Prognostic significance of plasma interleukin-6/-8 in pancreatic cancer patients receiving chemoimmunotherapy

doi:10.3748/wjg.v21.i39.11168

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 39

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7967)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-6) series, Tables (1-2) series.

Item

Count

PDF

492

WORD

263

HTML

3984

Figures (1-6)

194

Tables (1-2)

272

Sum=5205

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1049

Download

1713

Sum=2762

Oct 21, 2015 (publication date) through Nov 26, 2024

Times Cited of This Article

Times Cited (23)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Gastroenterol. Oct 21, 2015; 21(39): 11168-11178
Published online Oct 21, 2015. doi: 10.3748/wjg.v21.i39.11168

Table 1 Patient characteristics

No.	Sex	Age (yr)	Location	Size (mm)	Metastases	UICC stage	Vaccine (times)	OS (d)	PFS (d)	HLA type						Best overall tumor response
No.	Sex	Age (yr)	Location	Size (mm)	Metastases	UICC stage	Vaccine (times)	OS (d)	PFS (d)	HLA-A		DRB1		DPB1		Best overall tumor response
1	M	70	Body	22	Peritonitis	IV	35	582	440	02:01	24:02	04:05	15:02	05:01	09:01	Stable disease
2	M	68	Body	15	Liver, lymph nodes	IV	46	717	208	24:02	33:03	08:03	13:02	02:02	04:01	Stable disease
3	F	49	Head	18	Liver, peritonitis, lymph nodes	IV	7	133	26	02:01	24:02	04:05	09:01	02:02	05:01	Progressive disease
4	M	35	Body	25	Liver, lymph nodes	IV	6	283	147	02:01	-	09:01	15:01	02:01	05:01	Stable disease
5	F	72	Body	22	Peritonitis, lymph nodes	IV	14	215	109	02:06	24:02	08:02	12:01	02:01	05:01	Stable disease
6	F	69	Body-tail	45	Lymph nodes	IV	71+	1050+	545	24:02	33:03	13:02	15:01	04:01	13:01	Stable disease
7	M	39	Head-body	30	Peritonitis	IV	20	325	290	02:10	24:02	15:01	15:02	02:02	09:01	Stable disease

Stable disease conformation is determined at least for more than 2 mo. Ope: Operation; Cx: Chemotherapy; OS: Overall survival; PFS: Progression-free survival; HLA: Human leukocyte antigen.

Table 2 Wilms’ tumor 1-specific delayed-type hypersensitivity reactions

Patient	Gemcitabine		*HLA-A02:01**											*HLA-A24:02**											HLA-DRB1/DPB1
No.	Vaccine times											Vaccine times											Vaccine times
	Pre	Post	1	5	10	15	20	25	30	35	40	45	70	1	5	10	15	20	25	30	35	40	45	70	1	5	10	15	20	25	30	35	40	45	70
1	-	-	+	+	++	++	++	++	+	-	ND			+	+	++	++	++	++	+	-	ND			+	+	++	++	++	++	+	-	ND
2	-	-	-	-	-	-	-	-	-	-	-	-	ND	+	+	++	++	+	+	+	+	+	-	ND	+	+	++	++	+	+	+	+	+	-	ND
3	-	-	-	-	ND									-	-	ND									-	-	ND
4	-	-	-	-	ND									-	-	ND									-	-	ND
5	-	-	-	-	-	ND								-	-	-	ND								-	-	-	ND
6	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+	++	++	++	++	++	++	++	++	++	+	+	++	++	++	++	++	++	++	++	++
7	-	-	-	-	-	-	-	ND						-	-	+	+	-	ND							-	+	+	-	ND

Delayed-type hypersensitivity (DTH) erythema < 1 mm, +; DTH erythema 2-5 mm, ++; DTH erythema > 5 mm, not done (ND).

Citation: Tsukinaga S, Kajihara M, Takakura K, Ito Z, Kanai T, Saito K, Takami S, Kobayashi H, Matsumoto Y, Odahara S, Uchiyama K, Arakawa H, Okamoto M, Sugiyama H, Sumiyama K, Ohkusa T, Koido S. Prognostic significance of plasma interleukin-6/-8 in pancreatic cancer patients receiving chemoimmunotherapy. World J Gastroenterol 2015; 21(39): 11168-11178
URL: https://www.wjgnet.com/1007-9327/full/v21/i39/11168.htm
DOI: https://dx.doi.org/10.3748/wjg.v21.i39.11168